MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
- Registration Number
- NCT00430352
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 545
- adult patients, >=18 years of age;
- histologically confirmed grade 1, 2 or 3a follicular non-Hodgkin's lymphoma;
- patients who have received adequate (>=8 cycles) induction therapy with MabThera as first line treatment, or treatment for relapsed disease;
- demonstrated partial or complete response to induction therapy.
- stable or progressive disease after most recent induction therapy;
- transformation to high grade lymphoma;
- patients with prior or concomitant malignancies, except non-melanoma skin cancer or adequately treated in situ cancer of the cervix.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 rituximab [MabThera/Rituxan] -
- Primary Outcome Measures
Name Time Method Percentage of Participants With an Adverse Event (AE) - Overall Summary 24 months Data presented include percentage of participants with any AE, any infusion-related AE, any serious adverse event (SAE), any infusion-related SAE (counted separately from SAEs), death, and participants with toxicity as the primary cause for treatment discontinuation.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) - Time to Event Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.
Progression-Free Survival - Percentage of Participants With an Event Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.
Progression-Free Survival - Time to Event Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.
Event-Free Survival (EFS) - Percentage of Participants With an Event Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose The percentage of participants who experienced PD or death or required a next or new lymphoma treatment over a study period of 2 years with 1 year of follow-up. EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.
Event-Free Survival (EFS) - Time to Event Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.
Overall Survival (OS) - Percentage of Participants With an Event Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose As a measure of overall survival (OS), the percentage of participants who died over the study period of 2 years with 1 year of follow-up. OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.
Time to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose As a measure of time to NLT (TNLT), the percentage of participants with new lymphoma treatment over a study period of 2 years with 1 year of follow-up. TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.
Time to NLT - Time to Event Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.
Percentage of Participants With Response by Best Response to Study Treatment Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose Percentage of participants with complete response (CR), unconfirmed CR (CRu), no change, or progressive disease (PD). For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Where possible, assessment of response was based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (NHL).
Percentage of Participants With PR Who Converted to CRu Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose Percentage of participants with PR or CR(u) conversion while on rituximab maintenance therapy over a study period of 2 years with 1 year of follow-up. For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Assessment and definition of response was based on the International Workshop to Standardize Response Criteria for NHL.
Trial Locations
- Locations (177)
Mount Medical Center
🇦🇺Perth, Western Australia, Australia
Clinica Oncologica De Piracicaba Sc
🇧🇷Piracicaba, SP, Brazil
Dres.Andreas Karcher und Stefan Fuxius
🇩🇪Heidelberg, Germany
Hospital Churruca Visca; Haematology
🇦🇷Buenos Aires, Argentina
Hospital Mae de Deus
🇧🇷Porto Alegre, RS, Brazil
Centro de Tratamento Oncologico - Oncoclinica
🇧🇷Rio de Janeiro, RJ, Brazil
ONCOMED
🇧🇷Belo Horizonte, MG, Brazil
Laiko General Hospital - Uni of Athens; 1St Dept. of Internal Medicine
🇬🇷Athens, Greece
Centro Médico Carlos Ardila Lule
🇨🇴Bucaramanga, Colombia
Haematologisch-Onkologische Praxis; Dr. med. Christoph Maintz und Matthias Groschek
🇩🇪Wuerselen, Germany
Hospital Estadual do Servidor Publico; Hematologia
🇧🇷Sao Paulo, SP, Brazil
Märkische Kliniken GmbH, Klinikum Lüdenscheid; Hämatologie / Onkologie
🇩🇪Lüdenscheid, Germany
Theagenio Anticancer Hospital; Dept. of Haematology
🇬🇷Thessaloniki, Greece
Überörtliche Gemeinschaftspraxis Schwerpunkt Hämatologie, internistische Onkologie & Palliativmed.
🇩🇪Hamburg, Germany
Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
🇮🇹Aviano, Friuli-Venezia Giulia, Italy
Ospedale Vito Fazzi; Div. Oncoematologia
🇮🇹Lecce, Puglia, Italy
Stauferklinikum Schwäb.Gmünd
🇩🇪Mutlangen, Germany
Onko. Gemeinschaftspraxis Dres. Tigges/ Böning/ Abenhardt/ Bosse
🇩🇪München, Germany
Onkologische Schwerpunktpraxis (Eps-Gmbh)
🇩🇪Jena, Germany
Ospedale S. Gennaro; Divisione Di Ematologia
🇮🇹Napoli, Campania, Italy
Ichilov Sourasky Medical Center; Heamatology
🇮🇱Tel Aviv, Israel
Oncology & Radiotherapy Centre; Oncology
🇪🇬Cairo, Egypt
Chaim Sheba Medical Center; Hematology BMT & CBB
🇮🇱Ramat Gan, Israel
Diakonie-Klinikum Klinik für Innere Medizin III Abt.Hämatologie, intern. Onkologie und Palliativmedi
🇩🇪Schwäbisch-Hall, Germany
A.O. Universitaria Policlinico Di Modena; Ematologia
🇮🇹Modena, Emilia-Romagna, Italy
Rambam Medical Center; Heamatology & Bone Marrow Transplantation
🇮🇱Haifa, Israel
Onkologische Schwerpunktpraxis Kurfürstendamm
🇩🇪Berlin, Germany
Attiko Hospital; Haematology Clinic
🇬🇷Athens, Greece
Wolfson Mc; Haematology
🇮🇱Holon, Israel
Dres.Christian Sperling und Claudia Schelenz
🇩🇪Berlin, Germany
Hadassah Ein Karem Hospital; Haematology
🇮🇱Jerusalem, Israel
Onkologische Schwerpunktpraxis; Herrn Dr. Med. Bertram
🇩🇪Hamburg, Germany
Arcispedale S. Anna; Sezione Di Ematologia
🇮🇹Ferrara, Emilia-Romagna, Italy
Gemeinschaftspraxis Dres. Schröder, Sieg
🇩🇪Mülheim, Germany
Dres.Ulrich Hutzschenreuter und Uwe Sauer
🇩🇪Nordhorn, Germany
Azienda Ospedaliera S. Maria della Misericordia; Ematologia
🇮🇹Perugia, Umbria, Italy
A.O. Universitaria S. Martino Di Genova; Ematologia 1
🇮🇹Genova, Liguria, Italy
Research Inst. of Hematology & Blood Transfusion ; Hematology
🇷🇺St Petersburg, Russian Federation
Onkologische Praxis Oldenburg; Dres. Otremba, Reschke, Zirpel, Kühn und Ruff
🇩🇪Oldenburg, Germany
Regional Clinical Hospital; Hematology
🇷🇺Yaroslavl, Russian Federation
Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V
🇩🇪Heidelberg, Germany
Pavlov State Medical Uni ; Bone Marrow Transplantation Clinic
🇷🇺St Petersburg, Russian Federation
A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
🇮🇹Bologna, Emilia-Romagna, Italy
Regional Clinical Hospital N.A. Semashko; Hematology
🇷🇺Nizhny Novgorod, Russian Federation
City Clinical Hospital After Botkin; Hematology
🇷🇺Moscow, Russian Federation
Complejo Asistencial Universitario De Burgos; Servicio de Oncologia
🇪🇸Burgos, Spain
Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
🇪🇸Murcia, Spain
Uddevalla Sjukhus; Medicinkliniken
🇸🇪Uddevalla, Sweden
Hacettepe Uni Medical Faculty; Hematology
🇹🇷Ankara, Turkey
Istanbul Uni Capa Hospital; Hematology
🇹🇷Istanbul, Turkey
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
🇷🇺Kazan, Russian Federation
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
🇪🇸Jaen, Spain
City Hematological Center of Clinical Hospital #2; Hematology
🇷🇺Novosibirsk, Russian Federation
Ospedale Di Vicenza; Nefrologia, Ematologia
🇮🇹Vicenza, Veneto, Italy
Sunderby Sjukhus; Medicinkliniken
🇸🇪Luleå, Sweden
Vladimirskiy Regional Scientific Research Inst. ; Hematology
🇷🇺Moscow, Russian Federation
Blokhin Cancer Research Center; Clinical Oncology
🇷🇺Moscow, Russian Federation
Hospital El Bierzo; Servicio de Oncologia
🇪🇸Leon, Spain
Hospital Costa del Sol; Servicio de Hematologia
🇪🇸Malaga, Spain
Skånes Universitetssjukhus; Kliniska Forskningsenheten Onkologimottagning medicinsk behandling
🇸🇪Malmö, Sweden
Gazi Uni Medical School; Hematology
🇹🇷Ankara, Turkey
Hospital General de Castellon; Servicio de Hematologia
🇪🇸Castellon, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
🇪🇸Valencia, Spain
Hospital Universitario Virgen Macarena; Servicio de Hematologia
🇪🇸Sevilla, Spain
Bashkirian Republican Clinical Oncology Dispensary
🇷🇺UFA, Russian Federation
Ankara Numune Egitim Ve Arastirma Hastanesi; Hematoloji Klinigi
🇹🇷Ankara, Turkey
Az. Osp. Uni Ria Policlinico Tor Vergata; Unita Di Ematologia
🇮🇹Roma, Lazio, Italy
Univ. Cattolica La Sapienza; Cattedra Di Ematologia
🇮🇹Roma, Lazio, Italy
A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia
🇮🇹Torrette Di Ancona, Marche, Italy
Clinca San Jose; Haematology
🇲🇽Obregon, Mexico
Issstep Puebla, ; Haematology
🇲🇽Puebla, Mexico
Fundeni Clinical Inst. ; Hematology Dept
🇷🇴Bucharest, Romania
Uni Hospital; Clinic of Haematology
🇸🇰Kosice, Slovakia
Uni Hospital ; Dept. of Haematol. & Transfusion Medicine
🇸🇰Martin, Slovakia
Ospedale Cardarelli; Divisione Di Ematologia
🇮🇹Napoli, Campania, Italy
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia
🇮🇹Brescia, Lombardia, Italy
Istituto S. Raffaele Monte Tabor; Divisione Ematologia E Utmo
🇮🇹Milano, Lombardia, Italy
Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico
🇮🇹Milano, Lombardia, Italy
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
🇮🇹Milano, Lombardia, Italy
ASST DI MONZA; Ematologia
🇮🇹Monza, Lombardia, Italy
Irccs Policlinico San Matteo; Divisione Di Ematologia
🇮🇹Pavia, Lombardia, Italy
Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico
🇮🇹Candiolo, Piemonte, Italy
Az. Osp. S. Croce Ospedale Generale; Sezione Di Ematologia
🇮🇹Cuneo, Piemonte, Italy
Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad
🇮🇹Novara, Piemonte, Italy
Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica
🇮🇹Bari, Puglia, Italy
Az. Osp. C. Panico; Rep. Ematologia E Trapianto
🇮🇹Tricase - Le, Puglia, Italy
Ospedale Oncologico A Businco-Cagliari; Ematologia Sez.
🇮🇹Cagliari, Sardegna, Italy
Ospedale V. Cervello; U.O. Ematologia E Trapianti
🇮🇹Palermo, Sicilia, Italy
Ospedale Ferrarotto; Divisione Di Ematologia
🇮🇹Via S. Sofia 78, Sicilia, Italy
Az. Osp. Di Careggi; Divisione Di Ematologia
🇮🇹Firenze, Toscana, Italy
Ospedale Santa Chiara; Unita Operativa Di Ematologia
🇮🇹Pisa, Toscana, Italy
A.O. Universitaria Senese; Ematologia
🇮🇹Siena, Toscana, Italy
Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia
🇮🇹Padova, Veneto, Italy
Laenssjukhuset; Medicinkliniken/Hematologsektionen
🇸🇪Halmstad, Sweden
Länssjukhuset Sundsvall-Härnösand, Medicinkliniken
🇸🇪Sundsvall, Sweden
Akademiska sjukhuset, Onkologkliniken
🇸🇪Uppsala, Sweden
CEHON
🇧🇷Salvador, BA, Brazil
Hospital Sao Lucas - PUCRS
🇧🇷Porto Alegre, RS, Brazil
Praxis für Onkologie und Hämatologie
🇩🇪Recklinghausen, Germany
Internistische Gemeinschaftspraxis Dres. Hoering/Von Ehr/Responde
🇩🇪Stuttgart, Germany
Stavropol Clinical Oncology Dispansary
🇷🇺Stavropol, Russian Federation
Ulyanovsk Regional Oncology Dispensary; Chemotherapy
🇷🇺Ulyanovsk, Russian Federation
Rostov State Medical Uni ; Hematology
🇷🇺Rostov-na-donu, Russian Federation
Regional Oncology Center; Chemotherapy
🇷🇺Volgograd, Russian Federation
Hospital das Clinicas - UNICAMP; Hemoterapia
🇧🇷Campinas, SP, Brazil
Wollongong Hospital; Cancer Services
🇦🇺Wollongong, New South Wales, Australia
Hospital Alemao Oswaldo Cruz; Oncologia
🇧🇷Sao Paulo, SP, Brazil
University "Mother Theresa" Hospital Center; Oncology Department
🇦🇱Tirana, Albania
Academia Nacional de Medicina; Inst. de Cardiologia
🇦🇷Buenos Aires, Argentina
Fundaleu; Haematology
🇦🇷Buenos Aires, Argentina
Instituo Lavalle de Oncologia; Hematology
🇦🇷Bahia Blanca, Argentina
Hospital Jr Vidal; Jefe de Servicio de Clinica Medica/Hematologia
🇦🇷Corrientes, Argentina
Sanatorio Allende; Haematology
🇦🇷Córdoba, Argentina
HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto OncologÃa
🇦🇷Córdoba, Argentina
Hospital General San Martin; Haematology
🇦🇷La Plata, Argentina
Uni Hospital Mostar
🇧🇦Mostar, Bosnia and Herzegovina
Liverpool Hospital; Haematology
🇦🇺Liverpool, New South Wales, Australia
Royal Brisbane Hospital; Oncology Department
🇦🇺Brisbane, Queensland, Australia
Haematology & Oncology Clinics of Australia, Mater Medical Centre
🇦🇺South Brisbane, Queensland, Australia
Nucleo de Oncologia da Bahia - NOB
🇧🇷Salvador, Bahia, BA, Brazil
Centro de Pesquisas Oncologicas - CEPON
🇧🇷Florianopolis, SC, Brazil
Hospital das Clinicas - UFRGS; Medicina Interna
🇧🇷Porto Alegre, RS, Brazil
UMHAT Dr Georgi Stranski; Hematology
🇧🇬Pleven, Bulgaria
Hospital das Clinicas - FMUSP, Oncologia
🇧🇷Sao Paulo, SP, Brazil
National Center of Hematology & Transfusiology; Clinical Unit, Clinic of Hematology
🇧🇬Sofia, Bulgaria
UMHAT Alexandrovska EAD; Hematology
🇧🇬Sofia, Bulgaria
Clinical Hospital Centre Split; Dept Of Hematology
ðŸ‡ðŸ‡·Split, Croatia
Hospital José Carrasco; Oncology Service
🇪🇨Cuenca, Ecuador
Mhat Sveta Marina; Dept. of Haematology
🇧🇬Varna, Bulgaria
Clinical Hospital Centre Dubrava; Hematology Department
ðŸ‡ðŸ‡·Zagreb, Croatia
University Hospital Center Zagreb; Haematology Department
ðŸ‡ðŸ‡·Zagreb, Croatia
Kymenlaakson keskussairaala
🇫🇮Kotka, Finland
Internist; Praxis Für Haemotologie & Onkologie
🇩🇪Bad Soden, Germany
Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin
🇩🇪Bonn, Germany
Dres. Matthias Adler Oliver Marschal und Andreas Pies
🇩🇪Braunschweig, Germany
Internistische Praxis Dr. Plingen
🇩🇪Düsseldorf, Germany
Gemeinschaftspraxis
🇩🇪Duisburg, Germany
Internistische Schwerpunktpraxis Erlangen
🇩🇪Erlangen, Germany
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
🇩🇪Freiburg, Germany
Onkologische Gemeinschaftspraxis, Prof. Dr. Gropp, Dr. Depenbusch und Dr. Rösel
🇩🇪Gütersloh, Germany
A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1
🇮🇹Torino, Piemonte, Italy
A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia
🇮🇹Torino, Piemonte, Italy
Leningrad Regional Clinical Hospital; Hematology #1
🇷🇺St Petersburg, Russian Federation
National Oncology Inst. ; Dept. of Haematology
🇸🇰Bratislava, Slovakia
Hospital Generla de Ciudad Real; Servicio de Oncologia
🇪🇸Ciudad Real, Spain
Ege Uni Medical School; Hematology
🇹🇷Izmir, Turkey
Clinic of Oncology, University Clinical Center Sarajevo
🇧🇦Sarajevo, Bosnia and Herzegovina
Ospedale S. Eugenio; Divisione Di Ematologia
🇮🇹Roma, Lazio, Italy
Spitalul Clinic Coltea; Clinica de Hematologie
🇷🇴Bucuresti, Romania
Spitalul Clinic Judetean de Urgenta Sf. Spiridon Iasi, Clinica de Hematologie
🇷🇴Iasi, Romania
Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie
🇷🇴Targu-mures, Romania
Fakultna Nemocnica Roosevelta; Dept. of Haematology
🇸🇰Banska Bystrica, Slovakia
UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie
🇨ðŸ‡Zürich, Switzerland
Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia
🇮🇹Pescara, Abruzzo, Italy
University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept
🇧🇦Banja Luka, Bosnia and Herzegovina
Hospital Pablo Tobon Uribe
🇨🇴Medellin-Antioquia, Colombia
Kanta-Hämeen Keskussairaala; Dept of Internal Medicine, Hematology
🇫🇮Haemeenlinna, Finland
Hospital Español de Mexico
🇲🇽Mexico City, Mexico
Hospital Regional Issste; Oncologia
🇲🇽Monterrey, Mexico
Andreas Klinik; Onko-Hämatologisches Zentrum Cham Zug
🇨ðŸ‡Cham, Switzerland
Inst. of Hematology
🇧🇦Kasindo, Bosnia and Herzegovina
Umhat S. George; Hematology
🇧🇬Plovdiv, Bulgaria
Hospital Carlos Andrade Marin; Servicio de OncologÃa
🇪🇨Quito, Ecuador
Päijät-Hämeen Keskussairaala; Dept of Internal Medicine, Hematology
🇫🇮Lahti, Finland
Uni Cattolica; Divisione Di Ematologia
🇮🇹Roma, Lazio, Italy
Spitalul Clinic Judetean de Urgenta Brasov,Clinica de Hematologie
🇷🇴Brasov, Romania
Institute of Oncology Ljubljana
🇸🇮Ljubljana, Slovenia
Ospedale Civile; S.C. Ematologia
🇮🇹Pesaro, Marche, Italy
Satakunnan Keskussairaala; Sisaetauti Osasto
🇫🇮Pori, Finland
Issste; Haematology
🇲🇽Chihuahua, Mexico
Hospital Cima (Centro Internacional de Medicina) ; Haematology
🇲🇽Chihuahua, Mexico
Hospital Central de Pemex Norte Azcapotzalco
🇲🇽Mexico City, Mexico
Oncology Inst. Cluj-Napoca; Cancer Dept
🇷🇴Cluj-Napoca, Romania
Kantonsspital Graubünden;Onkologie und Hämatologie
🇨ðŸ‡Chur, Switzerland
Clinica Santa Chiara; Oncologia / Ematologia
🇨ðŸ‡Locarno, Switzerland
Az. Osp. Pugliese; Dh Oncologico
🇮🇹Catanzaro, Calabria, Italy
A.O.U. Policlinico di Modena-Dipartimento di Medicina Diagnostica, Clinica e di Sanità pubblica
🇮🇹Modena, Emilia-Romagna, Italy